文献速递消化系统肿瘤

意大利多中心胰腺癌患者队列中癌症易感基因的胚系致病性变异

Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients.
PubMed 文献 · Eur J Cancer · 2024-07-16

该研究在意大利多中心连续1200例胰腺癌患者中评估癌症易感基因胚系致病性变异(gPV)的患病率,发现CP-18核心基因组gPV患病率为11.5%(126/1092),CDKN2A gPV为2.6%(23/869),作者据此推荐所有胰腺癌患者进行多基因胚系检测。

要点

  • CP-18队列中11.5%(126/1092)患者携带至少1个基因的gPV。
  • gPV频率最高为ATM(3.1%)、BRCA2(2.9%)、BRCA1(1.6%)、CHEK2(1.1%)。
  • 所有亚组(含年龄>73、I-III期、无家族史/个人史)gPV风险均≥7%。

核心结论

  • 在该大型多中心连续且非选择的胰腺癌队列中,癌症易感基因和DNA损伤修复系统相关基因的gPV患病率显著。
  • 作者推荐所有胰腺癌患者进行多基因胚系检测(至少包括BRCA1-2、ATM、CDKN2A、PALB2),不论年龄、分期、个人史或家族史。

研究设计与样本

  • 研究为多中心队列,连续收集1200例任何年龄和分期的胰腺癌患者临床数据,均接受多基因胚系panel检测。
  • 在1092例接受18基因核心panel检测的患者(CP-18队列)和869例仅筛查CDKN2A的患者中,进行gPV频率和临床变量的描述性分析。

主要发现

  • CP-18队列中11.5%(126/1092)的患者携带至少1个基因的gPV。
  • gPV频率最高为ATM(3.1%)、BRCA2(2.9%)、BRCA1(1.6%)、CHEK2(1.1%)。
  • 携带任何CP-18基因gPV及BRCA1-2 gPV的患者较无gPV患者更年轻,且个人史或家族史癌症比例更高。
  • 所有亚组患者携带gPV的风险均≥7%,包括年龄>73岁、肿瘤分期I-III期及家族史/个人史阴性者。
  • CDKN2A gPV在2.6%(23/869)的患者中检出。

关键数值与推荐

  • CP-18队列gPV总患病率11.5%(126/1092)。
  • ATM gPV频率3.1%,BRCA2为2.9%,BRCA1为1.6%,CHEK2为1.1%。
  • CDKN2A gPV在869例筛查患者中为2.6%(23/869)。
  • 所有亚组(包括年龄>73岁、I-III期、家族史/个人史阴性)gPV风险≥7%。

临床怎么用

  • 作者推荐所有胰腺癌患者进行多基因胚系检测,至少包括BRCA1-2、ATM、CDKN2A、PALB2,不论年龄、分期、个人史或家族史。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIM: Germline BRCA1-2 test is routinely recommended in Pancreatic Cancer (PC) patients, due to its clinical-epidemiological relevance. Data on the prevalence of germline pathogenic variants (gPV) in other cancer predisposition and DNA Damage Repair (DDR) system-related genes in unselected PC cases are sparce in Italy. We assessed this prevalence in a multicentre cohort, to derive recommendations for PC patients. METHODS: Clinical data of 1200 consecutive PC patients, of any age and stage, tested with a multigene germline panel were collected. A descriptive analysis of gPV frequency and clinical variables was performed both in 1092 patients tested for an 18 genes core-panel (CP-18 cohort) and in 869 patients screened only for CDKN2A. RESULTS: 11.5 % (126/1092) of CP-18 cohort patients harbored a gPV in ≥ 1 gene. Highest gPV frequencies were detected in ATM (3.1 %), BRCA2 (2.9 %), BRCA1 (1.6 %), CHEK2 (1.1 %). Patients harboring any CP-18 gene and BRCA1-2 gPV were younger and with a higher rate of personal (PH) or family history (FH) of cancer when compared to no gPV patients. The risk of having a gPV was ≥ 7 % in all subgroups of patients, including those aged > 73, with tumor stage I-III and negative FH/PH. CDKN2A gPV were detected in 2.6 % (23/869) of patients. CONCLUSIONS: A remarkable prevalence of gPV in cancer predisposition and DDR genes is reported in this large multicentre cohort of consecutive and unselected PC patients. Therefore, we recommend multigene germline testing (at least including BRCA1-2, ATM, CDKN2A, PALB2) for all PC patients, irrespective of age, stage, PH/FH.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Orsi G, Carconi C, Ghiorzo P, et al. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Eur J Cancer. 2024. PMID: 39029294. doi:10.1016/j.ejca.2024.114226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。